NZYM B Novozymes A/S Class B

Combining EVP roles of Human Health Biosolutions and Strategy & Integration

Combining EVP roles of Human Health Biosolutions and Strategy & Integration

As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy & Integration. 

COPENHAGEN, Denmark – After successfully combining into one company, Novonesis is delivering strong results, progressing firmly on the integration, as well as realizing synergies across the company. As a next step on our integration journey, the EVP area of Strategy & Integration will combine with the Human Health Biosolutions sales area. Henrik Joerck Nielsen, currently Executive Vice President for Strategy & Integration, will step into the newly combined role as EVP Human Health Biosolutions & Strategy. Amy Byrick steps down as EVP for Human Health Biosolutions. The change to the Executive Leadership team will be effective no later than August 1, 2025. 

“Since combining into Novonesis in January 2024, we have made impressive progress in coming together as one company while delivering on our synergy targets. Throughout this integration journey, Henrik has orchestrated and driven the transformation and overall integration. Henrik’s strong strategic and business acumen, coupled with his background spanning R&D and commercial leadership within pharmaceuticals, nutrition and health, make him an excellent profile to further develop Novonesis’ Human Health business and ensure we continue to successfully execute on our strategy,” says Ester Baiget, CEO, Novonesis.

Amy Byrick will open a new chapter in her life and pursue a non-Executive career. She will therefore step down from her position as Executive Vice President of Human Health Biosolutions and leave the company by July 31. Amy joined Novozymes’ Executive Leadership Team in 2021 as EVP of Strategy & Transformation, and she was appointed Executive Vice President of Human Health Biosolutions in Novonesis in 2023. 

“I want to extend a heartful thank you to Amy for her extraordinary contribution and commitment to creating Novonesis and establishing our Human Health Biosolutions Business. Amy has been a key player in driving the combination of Novozymes and Chr. Hansen, and she has also been instrumental in ensuring that Novonesis is well-positioned to meet the evolving nutritional and health needs of a growing population. I send my warmest wishes to Amy as she embarks on this new chapter in her life,” says Ester Baiget. 



Attachment



EN
19/05/2025

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Please read the full announcement in PDF. Attachments

July 21, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Biosolutions could create more than 600,000 jobs and unlock hundreds o...

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But without urgent policy leadership and better regulation, Europe risks becoming the world’s best lab for solutions that scale elsewhere. Copenhagen, Denmark – 7 July 2025: Europe is on the verge of a job and growth boom if bio...

July 7, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated  1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Please read the full announcement in PDF. Attachment

June 30, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program As of June 20th, 2025, Novonesis has purchased an accumulated 1,660,344 shares with a transaction value of DKK 713,0 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million (DKK 746 million) in total during the remainder of 2025. Please read the full announcement in PDF  Attachment

June 23, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 19, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,343,678 shares, corresponding to 4.98% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...

June 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch